Axovant Sciences Ltd (NYSE:AXON)‘s stock had its “hold” rating reiterated by stock analysts at Robert W. Baird in a research report issued to clients and investors on Wednesday. They presently have a $6.00 target price on the biotechnology company’s stock.
Several other research analysts also recently weighed in on the company. BidaskClub downgraded Axovant Sciences from a “sell” rating to a “strong sell” rating in a research note on Friday, September 15th. Evercore ISI started coverage on Axovant Sciences in a report on Friday, September 8th. They set an “outperform” rating and a $30.00 price objective on the stock. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 price objective on the stock in a report on Monday, October 9th. Chardan Capital reaffirmed a “sell” rating and set a $3.00 price objective on shares of Axovant Sciences in a report on Saturday, September 23rd. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $30.00 price objective on shares of Axovant Sciences in a report on Monday, September 25th. Four analysts have rated the stock with a sell rating, four have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $14.13.
Axovant Sciences (NYSE:AXON) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.12).
COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/11/03/robert-w-baird-reiterates-hold-rating-for-axovant-sciences-ltd-axon.html.
A number of large investors have recently added to or reduced their stakes in AXON. Bank of America Corp DE raised its holdings in Axovant Sciences by 38.9% during the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares during the period. Legal & General Group Plc raised its holdings in Axovant Sciences by 20.2% during the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 1,168 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in Axovant Sciences during the 1st quarter valued at $219,000. American International Group Inc. raised its holdings in Axovant Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 998 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in Axovant Sciences by 38.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 2,789 shares during the period.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
What are top analysts saying about Axovant Sciences Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axovant Sciences Ltd and related companies.